Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients

Last updated: November 20, 2024
Sponsor: Weibing Miao, PhD
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Chronic Pain

Pain

Treatment

N/A

Clinical Study ID

NCT06701734
Chronic_pain_DPA714 PET
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Chronic pain is a major public health issue, which seriously affects patients' quality of life. Neuroinflammation is an important mechanism resulting in chronic pain. Translocator protein (TSPO) has served as a marker of microglial activation and neuroinflammation. 18F-DPA714, a tracer targeted TSPO, can be used to evaluate the microglial activation and neuroinflammation in vivo by PET imaging.Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands.The investigators aim to explore the clinical feasibility used 18F-DPA714 PET imaging to monitor microglial cells activation of center nervous system in chronic pain patients. This study might reveal significant neuroinflammatory process in the center nervous system of the chronic pain patients. The results of this study might provide a new biomarker of disease pathological progression and indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • chronic pain patients

  • Written informed consent was provided by the patients and their family

Exclusion

Exclusion Criteria:

  • history of head trauma , epilepsy, claustrophobia, rheumatic or autoimmune diseases,psychiatric disorders, severe somatic diseases (neurological,cardiovascular,etc.),previous heart or brain surgery, substance abuse, inability to refrain fromhypnotics, magnetic implants, pregnancy, lactation

Study Design

Total Participants: 60
Study Start date:
December 01, 2024
Estimated Completion Date:
December 31, 2028